Barclays lowered the firm's price target on Encompass Health to $140 from $153 and keeps an Overweight rating on the shares. The firm updated the company's model post the Q1 report. High occupancy rates may constrain Encompass' volume growth near-term, but there is evidence of further opportunity to meet demand with de novo development, the analyst tells investors in a research note.
